[go: up one dir, main page]

IL133348A0 - Stable insulin formulations - Google Patents

Stable insulin formulations

Info

Publication number
IL133348A0
IL133348A0 IL13334898A IL13334898A IL133348A0 IL 133348 A0 IL133348 A0 IL 133348A0 IL 13334898 A IL13334898 A IL 13334898A IL 13334898 A IL13334898 A IL 13334898A IL 133348 A0 IL133348 A0 IL 133348A0
Authority
IL
Israel
Prior art keywords
insulin formulations
stable insulin
stable
formulations
insulin
Prior art date
Application number
IL13334898A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL133348A0 publication Critical patent/IL133348A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL13334898A 1997-06-13 1998-06-11 Stable insulin formulations IL133348A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5308997P 1997-06-13 1997-06-13
PCT/US1998/012218 WO1998056406A1 (en) 1997-06-13 1998-06-11 Stable insulin formulations

Publications (1)

Publication Number Publication Date
IL133348A0 true IL133348A0 (en) 2001-04-30

Family

ID=21981869

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13334898A IL133348A0 (en) 1997-06-13 1998-06-11 Stable insulin formulations

Country Status (30)

Country Link
US (3) US6034054A (cs)
EP (1) EP0884053B1 (cs)
JP (1) JP2002504908A (cs)
KR (1) KR100597500B1 (cs)
CN (1) CN1293916C (cs)
AR (1) AR012894A1 (cs)
AT (2) ATE329612T1 (cs)
AU (1) AU734781B2 (cs)
BR (1) BR9810116B1 (cs)
CA (1) CA2295140C (cs)
CO (1) CO4750643A1 (cs)
CZ (1) CZ299637B6 (cs)
DE (2) DE69834956T2 (cs)
DK (1) DK0884053T3 (cs)
EA (1) EA002880B1 (cs)
ES (2) ES2264713T3 (cs)
HU (1) HUP0002877A3 (cs)
ID (1) ID24310A (cs)
IL (1) IL133348A0 (cs)
NO (1) NO996131L (cs)
NZ (1) NZ501382A (cs)
PE (1) PE79099A1 (cs)
PL (1) PL194244B1 (cs)
PT (2) PT884053E (cs)
SV (1) SV1998000065A (cs)
TR (1) TR199903036T2 (cs)
TW (1) TW577753B (cs)
UA (1) UA61109C2 (cs)
WO (1) WO1998056406A1 (cs)
ZA (1) ZA984697B (cs)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
ES2234560T3 (es) 1999-01-06 2005-07-01 Genentech, Inc. Variante mutante del factor de crecimiento de tipo insulina (igf-i).
HK1039065B (en) 1999-04-08 2004-04-16 Genentech, Inc. Composition based on oppositely-charged polypeptides
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1292324A2 (en) * 2000-05-05 2003-03-19 Novo Nordisk A/S Critical illness neuropathy
DE60133271T2 (de) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US20030199445A1 (en) * 2002-02-07 2003-10-23 Knudsen Lotte Bjerre Use of GLP-1 compound for treatment of critically ill patients
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
KR101123113B1 (ko) * 2002-07-29 2012-03-15 쎄라피콘 에스.알.엘. 코 펩티드 약학 제형
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
ES2391776T3 (es) * 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
JP5292572B2 (ja) 2004-12-27 2013-09-18 サイレンス・セラピューティクス・アーゲー コーティングされた脂質複合体およびそれらの使用
WO2006093222A1 (ja) * 2005-03-02 2006-09-08 Ajinomoto Co., Inc. インスリンの多量体形成阻害剤
EP1888117A1 (en) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilized polypeptide formulations
US8097584B2 (en) * 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007047948A2 (en) * 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
WO2007135117A2 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
US9023793B2 (en) * 2006-09-29 2015-05-05 Retrophin, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8114428B2 (en) * 2007-03-08 2012-02-14 Sbf Synthetic Bone Factory Gmbh Methods for manufacturing a composition for treating bone and/or cartilage defects
WO2008118387A2 (en) * 2007-03-23 2008-10-02 Wayne State University Erythrocyte atp-release modulators
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
PT2203181T (pt) * 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CN102066401A (zh) 2008-05-01 2011-05-18 艾瑞克有限公司 蛋白质制品
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
RU2011113823A (ru) 2008-09-10 2012-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
HUE048608T2 (hu) 2008-10-17 2020-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
JP5508438B2 (ja) 2009-01-28 2014-05-28 スマートセルズ・インコーポレイテツド 制御された薬物送達のための複合体に基づくシステム
CA2750223A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
BRPI1007466A2 (pt) 2009-01-28 2018-06-12 Smartcells Inc conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
WO2010099490A2 (en) 2009-02-27 2010-09-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
BRPI1014760B8 (pt) * 2009-06-26 2021-05-25 Novo Nordisk As preparação compreendendo insulina, nicotinamida e arginina
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
LT2498801T (lt) 2009-11-13 2018-05-10 Sanofi-Aventis Deutschland Gmbh Farmacinė kompozicija, apimanti despro36eksendin-4(1-39)-lys6-nh2 ir metioniną
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9068013B2 (en) 2010-07-28 2015-06-30 Smart Cells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
CA2806399A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102188367B (zh) * 2011-01-05 2012-11-07 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US20130345113A1 (en) * 2011-07-13 2013-12-26 Ronald E. Strohbehn Method of Use of Activated Functional Proteins to Improve Animal Health
AU2012285904C1 (en) 2011-07-15 2017-08-31 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
AU2012332556B2 (en) * 2011-10-31 2016-05-26 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CA2889165A1 (en) * 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
EP3016704A4 (en) * 2013-07-04 2017-03-08 Insuline Medical Ltd. Device, system and method for delivery of a long-acting drug
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
EP3091964A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
CN111658604A (zh) 2014-01-09 2020-09-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
AU2015204491B2 (en) * 2014-01-13 2021-01-07 Thermalin Inc. Rapid action insulin formulations and pharmaceutical delivery systems
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
FI3229828T3 (fi) 2014-12-12 2023-05-29 Sanofi Aventis Deutschland Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN105535942B (zh) * 2016-01-28 2017-07-28 通化东宝药业股份有限公司 一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
EP3419649B1 (en) * 2016-02-25 2025-04-09 Wockhardt Limited Stable pharmaceutical compositions comprising insulin glargine and insulin aspart and methods of preparation thereof
EP3468562A1 (en) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
AU2017378102B2 (en) 2016-12-16 2022-10-13 Novo Nordisk A/S Insulin containing pharmaceutical compositions
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
US12065381B2 (en) 2019-07-11 2024-08-20 Skyworks Solutions, Inc. Temperature-stable, low-dielectric constant material with an ultra-low loss tangent
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CN115843257A (zh) 2020-03-31 2023-03-24 原聚体科技公司 用于对邻位二醇的选择性响应性的缀合物
WO2022109078A1 (en) 2020-11-19 2022-05-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023017537A1 (en) 2021-08-12 2023-02-16 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체
CN119405787A (zh) * 2024-09-24 2025-02-11 广东东阳光生物制剂有限公司 一种高稳定性的高浓度含锌胰岛素制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1285023A (en) 1968-08-09 1972-08-09 Novo Terapeutisk Labor As Improvements in or relating to injectable insulin preparations
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS5767548A (en) * 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
JP2002500196A (ja) * 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物

Also Published As

Publication number Publication date
DE69834956T2 (de) 2007-05-24
EA200000014A1 (ru) 2000-06-26
ES2264713T3 (es) 2007-01-16
US6034054A (en) 2000-03-07
CA2295140A1 (en) 1998-12-17
DE69834956D1 (de) 2006-07-27
CA2295140C (en) 2010-09-14
US6551992B1 (en) 2003-04-22
KR100597500B1 (ko) 2006-07-10
US6906028B2 (en) 2005-06-14
HK1030747A1 (en) 2001-05-18
PL337324A1 (en) 2000-08-14
WO1998056406A1 (en) 1998-12-17
TR199903036T2 (xx) 2000-06-21
SV1998000065A (es) 1999-02-03
HUP0002877A2 (hu) 2001-01-29
PT884053E (pt) 2002-12-31
NO996131D0 (no) 1999-12-10
CN1293916C (zh) 2007-01-10
NZ501382A (en) 2001-08-31
JP2002504908A (ja) 2002-02-12
PL194244B1 (pl) 2007-05-31
BR9810116B1 (pt) 2009-05-05
BR9810116A (pt) 2000-08-08
ATE329612T1 (de) 2006-07-15
AU7837798A (en) 1998-12-30
EA002880B1 (ru) 2002-10-31
HUP0002877A3 (en) 2001-03-28
NO996131L (no) 2000-02-03
EP0884053A1 (en) 1998-12-16
CN1266371A (zh) 2000-09-13
KR20010013700A (ko) 2001-02-26
US20030104983A1 (en) 2003-06-05
DE69808695T2 (de) 2003-06-12
EP0884053B1 (en) 2002-10-16
UA61109C2 (uk) 2003-11-17
DK0884053T3 (da) 2002-11-04
CZ299637B6 (cs) 2008-10-01
AU734781B2 (en) 2001-06-21
CZ445199A3 (cs) 2000-07-12
DE69808695D1 (de) 2002-11-21
ZA984697B (en) 1999-12-01
PT1283051E (pt) 2006-08-31
CO4750643A1 (es) 1999-03-31
PE79099A1 (es) 1999-08-24
AR012894A1 (es) 2000-11-22
ATE226088T1 (de) 2002-11-15
ES2185113T3 (es) 2003-04-16
TW577753B (en) 2004-03-01
ID24310A (id) 2000-07-13

Similar Documents

Publication Publication Date Title
IL133348A0 (en) Stable insulin formulations
GB9715751D0 (en) Formulations
EP1049486A4 (en) GLP-1 FORMULATIONS
IL134901A0 (en) Insoluble insulin compositions
GB2291427B (en) Insulin analog formulations
HUP0002127A3 (en) Syringe
GB9713149D0 (en) Pharmaceutical formulations
EP0979660A4 (en) SYRINGE
IL135295A0 (en) 2-methyl-thieno-benzodiazepine formulation
GB2323531B (en) Therapeutic formulations
SI0884053T1 (en) Stable insulin formulations
HUP0004665A3 (en) Anaesthetic formulation
IL122920A (en) Castrointestinal drug composition
ZA9810773B (en) Revitalisation formulation
GB9700789D0 (en) Syringe
ZA982950B (en) Stabilized human papillomavirus formulations
GB9706957D0 (en) Formulation
GB9703099D0 (en) Formulations
GB9704521D0 (en) Formulations
GB9703100D0 (en) Formulations
GB9703101D0 (en) Formulations
HUP0001492A3 (en) Stabilized human papilomavirus formulations
GB9703607D0 (en) Pharmaceutical formulations
GB2329335B (en) Medicament
SG81218A1 (en) Syringe

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired